The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer

Oka, Toshiki; Hatano, Koji; Okuda, Yohei; Yamamoto, Akinaru; Uemura, Toshihiro; Yamamichi, Gaku; Tomiyama, Eisuke; Ishizuya, Yu; Yamamoto, Yoshiyuki; Kato, Taigo; Kawashima, Atsunari; Fujita, Kazutoshi; Nonomura, Norio

doi:https://doi.org/10.1007/s10147-022-02288-5

The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer

Oka, Toshiki; Hatano, Koji; Okuda, Yohei et al.

International Journal of Clinical Oncology, 2022, 28, 427-435

Number of Access:2,025（2025-10-12 12:23 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/90045

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
IntJClinOncol_Oka	pdf	None	593 KB	104	2023.12.29
Supplementary Table 1_RV1_2022.12.08	pdf	None	85.8 KB	43	2023.12.29	Supplementary Table 1.

Item Information

Output File Export EndNote Basic Export Mendeley

Title	The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer
Creator	NRID 1000060964385 1000060964385 CreatorName Oka, Toshiki
	NRID 1000060762234 1000060762234 researchmap permalink koji_hatano koji_hatano Scopus Author ID 14627167600 14627167600 CreatorName Hatano, Koji
	NRID 1000010964372 1000010964372 CreatorName Okuda, Yohei
	NRID 1000050909653 1000050909653 CreatorName Yamamoto, Akinaru
	NRID 1000060905941 1000060905941 CreatorName Uemura, Toshihiro
	NRID 1000040882262 1000040882262 CreatorName Yamamichi, Gaku
	NRID 1000040845244 1000040845244 CreatorName Tomiyama, Eisuke
	NRID 1000000783854 1000000783854 researchmap permalink okiishi okiishi CreatorName Ishizuya, Yu
	NRID 1000090759557 1000090759557 researchmap permalink yoshi229 yoshi229 ORCID 0000-0002-1271-3521 0000-0002-1271-3521 CreatorName Yamamoto, Yoshiyuki
	NRID 1000070648021 1000070648021 researchmap permalink taigokato taigokato Scopus Author ID 55414697500 55414697500 ORCID 0000-0002-8681-1407 0000-0002-8681-1407 CreatorName Kato, Taigo
	NRID 1000050746568 1000050746568 researchmap permalink akawashima akawashima Scopus Author ID 9846139400 9846139400 CreatorName Kawashima, Atsunari
	NRID 1000050636181 1000050636181 CreatorName Fujita, Kazutoshi
	NRID 1000030263263 1000030263263 researchmap permalink read0185096 read0185096 Scopus Author ID 7005880662 7005880662 CreatorName Nonomura, Norio
Subject	Androgen receptor antagonist
	Castration-resistant prostate cancer
	Enzalutamide
	Lymph node metastasis
	Progression-free survival
	Prostate-specific antigen
Description	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s10147-022-02288-5.
Abstract	Background: Enzalutamide is effective against castration-resistant prostate cancer (CRPC). However, it is unclear which patients would benefit more from enzalutamide treatment. Here, we analyzed patients who received enzalutamide as first-line therapy for CRPC and evaluated the factors that predict treatment response and prognosis. Methods: We retrospectively analyzed 101 patients treated with enzalutamide for CRPC at our institution. As primary endpoints we regarded the prostate-specific antigen (PSA) response rate and PSA–progression-free survival (PSA–PFS) from the start of enzalutamide treatment. Laboratory and imaging data were analyzed to predict treatment efficacy. Results: PSA reductions of ≥ 50% and ≥ 90% were observed in 78 (77%) and 47 (47%) patients, respectively, compared with the baseline. During the follow-up period, 67 (66%) patients showed PSA progression, with a median PSA–PFS of 11 months. Moreover, 31 patients (31%) died, with a median overall survival of 64 months. On multivariate analysis, lymph node metastases at the start of enzalutamide treatment [odds ratio (OR) 0.0575, 95% confidence interval (CI) 0.0105–0.316, p = 0.0010] and time to CRPC (OR 0.177, 95% CI 0.0428–0.731, p = 0.0167] were associated with ≥ 90% PSA response. Lymph node metastases (hazard ratio [HR] 3.00, 95% CI 1.48–6.09, p = 0.0023) and time to CRPC (HR 1.84, 95% CI 1.02–3.30, p = 0.0419) were also predictors of PSA–PFS on a multivariate model. Conclusions: Time to CRPC and lymph node metastasis were predictors of the PSA response rate and PSA–PFS.
Publisher	Springer
Source Title	International Journal of Clinical Oncology
Volume (Issue)	28
Page	427-435
Date of Issued	2022-12-29
Language	English
Handle URL	https://hdl.handle.net/11094/90045
PISSN	13419625
eISSN	14377772
NCID	AA11086579
Relation.isVersionOf	DOI (Publisher Version) https://doi.org/10.1007/s10147-022-02288-5
Access Rights	open access
oaire:version	Accepted Manuscript
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	International Journal of Clinical Oncology. 2022, 28, p. 427-435
DC.title	The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer
DC.creator	Oka, Toshiki
	Hatano, Koji
	Okuda, Yohei
	Yamamoto, Akinaru
	Uemura, Toshihiro
	Yamamichi, Gaku
	Tomiyama, Eisuke
	Ishizuya, Yu
	Yamamoto, Yoshiyuki
	Kato, Taigo
	Kawashima, Atsunari
	Fujita, Kazutoshi
	Nonomura, Norio
DC.publisher	Springer
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2022-12-29
DC.identifier	https://doi.org/10.1007/s10147-022-02288-5
DC.subject	Androgen receptor antagonist
	Castration-resistant prostate cancer
	Enzalutamide
	Lymph node metastasis
	Progression-free survival
	Prostate-specific antigen
DC.description	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s10147-022-02288-5.
DCTERMS.abstract	Background: Enzalutamide is effective against castration-resistant prostate cancer (CRPC). However, it is unclear which patients would benefit more from enzalutamide treatment. Here, we analyzed patients who received enzalutamide as first-line therapy for CRPC and evaluated the factors that predict treatment response and prognosis. Methods: We retrospectively analyzed 101 patients treated with enzalutamide for CRPC at our institution. As primary endpoints we regarded the prostate-specific antigen (PSA) response rate and PSA–progression-free survival (PSA–PFS) from the start of enzalutamide treatment. Laboratory and imaging data were analyzed to predict treatment efficacy. Results: PSA reductions of ≥ 50% and ≥ 90% were observed in 78 (77%) and 47 (47%) patients, respectively, compared with the baseline. During the follow-up period, 67 (66%) patients showed PSA progression, with a median PSA–PFS of 11 months. Moreover, 31 patients (31%) died, with a median overall survival of 64 months. On multivariate analysis, lymph node metastases at the start of enzalutamide treatment [odds ratio (OR) 0.0575, 95% confidence interval (CI) 0.0105–0.316, p = 0.0010] and time to CRPC (OR 0.177, 95% CI 0.0428–0.731, p = 0.0167] were associated with ≥ 90% PSA response. Lymph node metastases (hazard ratio [HR] 3.00, 95% CI 1.48–6.09, p = 0.0023) and time to CRPC (HR 1.84, 95% CI 1.02–3.30, p = 0.0419) were also predictors of PSA–PFS on a multivariate model. Conclusions: Time to CRPC and lymph node metastasis were predictors of the PSA response rate and PSA–PFS.
DC.format	90045
citation_title	The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer
citation_author	Oka, Toshiki
	Hatano, Koji
	Okuda, Yohei
	Yamamoto, Akinaru
	Uemura, Toshihiro
	Yamamichi, Gaku
	Tomiyama, Eisuke
	Ishizuya, Yu
	Yamamoto, Yoshiyuki
	Kato, Taigo
	Kawashima, Atsunari
	Fujita, Kazutoshi
	Nonomura, Norio
citation_publisher	Springer
citation_language	English
citation_date	2022-12-29
citation_journal_title	International Journal of Clinical Oncology
citation_volume	28
citation_firstpage	427
citation_lastpage	435
citation_doi	https://doi.org/10.1007/s10147-022-02288-5
citation_public_url	https://hdl.handle.net/11094/90045

The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer

Link to primary information

Item Information

Show details